These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 23720216)

  • 1. Nomogram for predicting survival in patients with unresectable and/or metastatic urothelial cancer who are treated with cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3012-9. PubMed ID: 23720216
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Posttreatment prognostic nomogram for patients with metastatic urothelial cancer completing first-line cisplatin-based chemotherapy.
    Galsky MD; Moshier E; Krege S; Lin CC; Hahn N; Ecke T; Sonpavde G; Pond G; Godbold J; Oh WK; Bamias A
    Urol Oncol; 2014 Jan; 32(1):48.e1-8. PubMed ID: 24055428
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relationship between 6- and 9-month progression-free survival and overall survival in patients with metastatic urothelial cancer treated with first-line cisplatin-based chemotherapy.
    Galsky MD; Krege S; Lin CC; Hahn N; Ecke T; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
    Cancer; 2013 Aug; 119(16):3020-6. PubMed ID: 23720197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nomogram-based Prediction of Overall Survival in Patients with Metastatic Urothelial Carcinoma Receiving First-line Platinum-based Chemotherapy: Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC).
    Necchi A; Sonpavde G; Lo Vullo S; Giardiello D; Bamias A; Crabb SJ; Harshman LC; Bellmunt J; De Giorgi U; Sternberg CN; Cerbone L; Ladoire S; Wong YN; Yu EY; Chowdhury S; Niegisch G; Srinivas S; Vaishampayan UN; Pal SK; Agarwal N; Alva A; Baniel J; Golshayan AR; Morales-Barrera R; Bowles DW; Milowsky MI; Theodore C; Berthold DR; Daugaard G; Sridhar SS; Powles T; Rosenberg JE; Galsky MD; Mariani L;
    Eur Urol; 2017 Feb; 71(2):281-289. PubMed ID: 27726966
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder.
    Karakiewicz PI; Shariat SF; Palapattu GS; Gilad AE; Lotan Y; Rogers CG; Vazina A; Gupta A; Bastian PJ; Perrotte P; Sagalowsky AI; Schoenberg M; Lerner SP
    J Urol; 2006 Oct; 176(4 Pt 1):1354-61; discussion 1361-2. PubMed ID: 16952631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-based combination chemotherapy in septuagenarians with metastatic urothelial cancer.
    Galsky MD; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Bamias A
    Urol Oncol; 2014 Jan; 32(1):30.e15-21. PubMed ID: 23428534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant chemotherapy for invasive urothelial cancer: experience with a methotrexate, vincristine, cisplatin, cyclophosphamide, adriamycin and bleomycin (MVP-CAB) regimen: a preliminary report.
    Gohji K; Higuchi A; Maruyama S; Minayoshi K; Fujii A; Itoh N; Hasunuma Y; Tanaka H; Izumi T
    Jpn J Clin Oncol; 1993 Oct; 23(5):291-8. PubMed ID: 7693990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. External validation of preoperative and postoperative nomograms for prediction of cancer-specific survival, overall survival and recurrence after robot-assisted radical cystectomy for urothelial carcinoma of the bladder.
    Al-Daghmin A; English S; Kauffman EC; Din R; Khan A; Syed JR; Sztorc J; Mehedint D; Sharif M; Shi Y; Wilding G; Guru KA
    BJU Int; 2014 Aug; 114(2):253-60. PubMed ID: 24119175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of survival following first-line chemotherapy in men with castration-resistant metastatic prostate cancer.
    Armstrong AJ; Garrett-Mayer E; de Wit R; Tannock I; Eisenberger M
    Clin Cancer Res; 2010 Jan; 16(1):203-11. PubMed ID: 20008841
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of cystectomy, and perioperative methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy on the risk and pattern of relapse in patients with muscle invasive bladder cancer.
    Ennis RD; Petrylak DP; Singh P; Bagiella E; O'Toole KM; Benson MC; Olsson CA
    J Urol; 2000 May; 163(5):1413-8. PubMed ID: 10751847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic factors for metastatic urothelial carcinoma treated with cisplatin and 5-fluorouracil-based regimens.
    Lin CC; Hsu CH; Huang CY; Tsai YC; Huang KH; Cheng AL; Pu YS
    Urology; 2007 Mar; 69(3):479-84. PubMed ID: 17382149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Second-Line Chemotherapy for Metastatic Urothelial Carcinoma: Importance of Lymph Node-Only Metastasis as a Prognostic Factor and Construction of a Prognostic Model.
    Salah S; Lee JL; Rozzi A; Kitamura H; Matsumoto K; Srinivas S; Morales-Barrera R; Carles J; Al-Wardat R; Al-Rabi K; Maakoseh M
    Clin Genitourin Cancer; 2016 Jun; 14(3):255-60. PubMed ID: 26552764
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors and long-term survivorship in patients with recurrent or metastatic carcinoma of the head and neck.
    Argiris A; Li Y; Forastiere A
    Cancer; 2004 Nov; 101(10):2222-9. PubMed ID: 15452834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can patient selection for bladder preservation be based on response to chemotherapy?
    Sternberg CN; Pansadoro V; Calabrò F; Schnetzer S; Giannarelli D; Emiliozzi P; De Paula F; Scarpone P; De Carli P; Pizzo M; Platania A; Amini M
    Cancer; 2003 Apr; 97(7):1644-52. PubMed ID: 12655521
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The impact of gender on outcomes in patients with metastatic urothelial carcinoma.
    Haines L; Bamias A; Krege S; Lin CC; Hahn N; Ecke TH; Moshier E; Sonpavde G; Godbold J; Oh WK; Galsky MD
    Clin Genitourin Cancer; 2013 Sep; 11(3):346-52. PubMed ID: 23673281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus MVAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group.
    Bamias A; Aravantinos G; Deliveliotis C; Bafaloukos D; Kalofonos C; Xiros N; Zervas A; Mitropoulos D; Samantas E; Pectasides D; Papakostas P; Gika D; Kourousis C; Koutras A; Papadimitriou C; Bamias C; Kosmidis P; Dimopoulos MA;
    J Clin Oncol; 2004 Jan; 22(2):220-8. PubMed ID: 14665607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative prognostic nomogram (probability table) for renal cell carcinoma based on TNM classification.
    Kanao K; Mizuno R; Kikuchi E; Miyajima A; Nakagawa K; Ohigashi T; Nakashima J; Oya M
    J Urol; 2009 Feb; 181(2):480-5; discussion 485. PubMed ID: 19100568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis.
    Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK
    Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nomograms predicting survival of patients with unresectable or metastatic gastric cancer who receive combination cytotoxic chemotherapy as first-line treatment.
    Kim SY; Yoon MJ; Park YI; Kim MJ; Nam BH; Park SR
    Gastric Cancer; 2018 May; 21(3):453-463. PubMed ID: 28828688
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II study of methotrexate, vinblastine, doxorubicin, and cisplatin in patients with squamous cell carcinoma of the upper respiratory or alimentary passages of the head and neck.
    Okuno SH; Mailliard JA; Suman VJ; Edmonson JH; Creagan ET; Nair S; Levitt R; Kugler JW
    Cancer; 2002 Apr; 94(8):2224-31. PubMed ID: 12001121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.